SCHEMBL12819982

SCHEMBL12819982

CN(C)CC(=O)N[C@H]1CC[C@H](NI)CC1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAOA P21397 1/20 0.42
GAA P10253 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.37
NPSR1 Q6W5P4 1/20 0.37
MAPT P10636 1/20 0.36
SMO Q99835 2/20 0.36
KMT2A Q03164 2/20 0.35
EPHX1 P07099 1/20 0.35
HPGD P15428 1/20 0.35
LMNA P02545 1/20 0.35
HDAC3 O15379 1/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC2 Q92769 1/20 0.35
HDAC10 Q969S8 1/20 0.35
HDAC11 Q96DB2 1/20 0.35
HDAC8 Q9BY41 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
HTT P42858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4191188 0.90 MAOA (0.47) MAOAGAASMN1; SMN2NPSR1MAPT
SCHEMBL9027751 0.83 EPHX1 (0.48) MAOAGAASMN1; SMN2MAPTEPHX1
SCHEMBL9027748 0.83 EPHX1 (0.48) MAOAGAASMN1; SMN2MAPTEPHX1
SCHEMBL1908699 0.83 MAOA (0.43) MAOAGAASMN1; SMN2NPSR1MAPT
SCHEMBL9029685 0.83 EPHX1 (0.48) MAOAGAASMN1; SMN2MAPTEPHX1
SCHEMBL12819865 0.82 SMN1; SMN2 (0.43) SMN1; SMN2NPSR1MAPTKMT2AHPGD
SCHEMBL21213732 0.81 SMYD3 (0.49) MAOAGAA
SCHEMBL21198215 0.81 SMYD3 (0.49) MAOAGAA
SCHEMBL16374937 0.81 SMYD3 (0.49) MAOAGAA
SCHEMBL18629569 0.81 NPSR1 (0.56) SMN1; SMN2NPSR1MAPTKMT2AEPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011035417-A1 HSP-90 BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND THEIR USE FN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES AEGERA THERAPEUTICS INC. (CA) 2011-03-31 WO disclosed